

RELAX-AHF shows first positive findings in HFpEF patients

May 26 2013

Serelaxin may be more effective for relieving dyspnea in heart failure with preserved ejection fraction (HFpEF) than reduced (HFrEF) during the first 24 hours, according to results from RELAX-AHF presented in today's late breaking trial session¹ at the Heart Failure Congress 2013. Results were also presented from VIVID, the first trial of the anti-diabetes drug vildagliptin in patients with heart failure.

The Heart Failure Congress is the main annual meeting of the Heart Failure Association of the [European Society of Cardiology](#) and is being held 25-28 May in Lisbon, Portugal. [Link to congress](#)

Many [patients](#) with [acute heart failure](#) (AHF) have preserved [ejection fraction](#) but there is a lack of evidence based therapies for this population. In a sub-group analysis, investigators of the Relaxin in Acute Heart Failure (RELAX-AHF) trial addressed the question of whether serelaxin was equally effective in AHF patients with HFpEF and HFrEF.

RELAX-AHF was a double blinded, randomised, placebo controlled trial in which 1161 AHF patients from 96 sites were randomised to 48 hour infusion of serelaxin or placebo within 16 hours of presentation. The primary efficacy endpoint was the effect on dyspnea in the short term (6, 12 and 24 hours) and at 5 days. Secondary efficacy endpoints were [cardiovascular death](#) or rehospitalisation for heart or [renal failure](#), and days alive and out of hospital through day 60. All-cause death and cardiovascular death through day 180 were also evaluated.

Serelaxin induced similar dyspnea relief in HFpEF and HFrEF patients at day 5 but was more effective in the HFpEF group in the first 24 hours. There were no differences between HFpEF and HFrEF patients in the effect of serelaxin on the secondary endpoints. Serelaxin had similar benefits on mortality in patients with HFpEF and HFrEF.

Presenter Professor Gerasimos Filippatos (Greece) said: "RELAX-AHF is the first trial to give positive findings in patients with acute heart failure and preserved ejection fraction, a large population with unmet treatment needs. Serelaxin is at least as effective in AHF patients with HFpEF for relieving [dyspnea](#) during the first 24 hours and had a similar effect on rehospitalisation and survival in HFrEF and HFpEF patients."

The Vildagliptin in Ventricular Dysfunction Diabetes (VIVIDDD) trial investigated the effects of the DPP4 inhibitor vildagliptin in patients with type 2 diabetes and HFrEF (left ventricular ejection fraction [LVEF])

Citation: RELAX-AHF shows first positive findings in HFpEF patients (2013, May 26) retrieved 18 April 2024 from <https://medicalxpress.com/news/2013-05-relax-ahf-positive-hfpef-patients.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.